Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115095
Chunk: 551

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 551
---
 Warrant for cash. |

| • |     | On July 1, 2024, the Registrant issued 10,000,000 shares of Common Stock to a law firm, pursuant to a stock issuance agreement dated as of such date, as a retainer for legal services to be provided by such law firm to the Registrant and its subsidiaries following such date, and as payment for prior services provided to the Registrant, to be held by such law firm until such time as such shares are applied against the outstanding legal fees or returned to us, in each case in accordance with the terms of such agreement. |

| • |     | On July 16, 2024, the Registrant issued a warrant to purchase up to an aggregate of 250,000 shares of Common Stock (the “Fee Warrant”) pursuant to the Tranche B Letter Agreement that the Registrant entered into with IVI 66766 LLC, a Delaware limited liability company, dated July 16, 2024. The exercise price of the Fee Warrant is $1.20 per share. The Registrant received $0.3 million from the exercise of the Fee Warrant, when it was exercised in full in October 2024. |

The Registrant issued the foregoing securities in transactions not involving an underwriter and not requiring registration under Section 5 of the Securities Act in reliance on the exemption afforded by Section 4(a)(2) thereof. II-3

Item 16. Exhibits and Financial Statements Schedules. (a) Exhibits The following exhibits are filed as part of this registration statement:

| Exhibit 
 Number  |     | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 2.1

#    |     | Agreement and Plan of Merger, dated as of March 18, 2019, by and among Scilex Holding Company, Sigma Merger Sub, Inc., Semnur Pharmaceuticals, Inc., Fortis Advisors LLC, solely as the representative of the Equityholders and, solely with respect to Section 1.8(a), Section 3.11 and Article X, Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 of Amendment No. 1 of Vickers’s Form S-4 (File No. 333-264941), filed with the SEC on June 27, 2022).                                                         |
| 2.2     |     | Amendment No. 1 to Agreement and Plan of Merger, dated as